Pertuzumab news

All news on Pertuzumab (also known as Perjeta and 2C4): plants, production capacities, investments and involved companies.

2 June 2026

Roche: FDA accepts priority‑review NDA for giredestrant in ER‑positive early‑stage breast cancer

FDA accepted priority NDA for oral SERD giredestrant as adjuvant in ER‑positive, HER2‑negative stage I–III breast cancer after phase III lidERA showed 30% iDFS risk reduction; PDUFA 30 Nov 2026.

Who will be producing Pertuzumab in the future?

Find out with chemXplore Alpha

Learn more